Jagasia M, Lazaryan A, Bachier CR, Salhotra A, Weisdorf DJ, Zoghi B, et al. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. J Clin Oncol. 2021;39:1888–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138:2278–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zeiser R, Lee SJ. Three US Food and Drug Administration-approved therapies for chronic GVHD. Blood. 2022;139:1642–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma R, Holtzman NG, Pusic I, Cutler C, Treister N, Mehta RS, et al. Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study. Blood Adv. 2025;9:3479–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee SJ, Pavletic S, Blazar BR, Yao Y, Ji R, Marshall K, et al. Belumosudil for Chronic Graft-Versus-Host Disease: Analysis of Long-Term Results from the KD025-208 and ROCKstar Studies. Transpl Cell Ther. 2025;31:434 e1–e10.

Google Scholar 

Michonneau D, Malard F, Le Grand S, Magro L, D’Aveni M, Tudesq JJ, et al. Efficacy and safety of belumosudil for treatment of cGVHD: multicenter retrospective analysis of the French cohort of the compassionate use program, on behalf of the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transpl. 2025;60:779–86.

Article  CAS  Google Scholar 

Heidenreich S, Egger-Heidrich K, Halter JP, Jost L, Stolzel F, Perl M, et al. Safety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment - a retrospective, German-Swiss multicenter real-world data analysis. Bone Marrow Transpl. 2025;60:439–46.

Article  CAS  Google Scholar 

Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389–401.e1.

Article  Google Scholar 

Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transpl. 2015;21:984–99.

Article  Google Scholar 

DeFilipp Z, Kim HT, Yang Z, Noonan J, Blazar BR, Lee SJ, et al. Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials. Blood Adv. 2022;6:6263–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stepanyants V, Li H, Cenin D, Edwards J, Brunstein C, Kalaycio M, et al. Infections in steroid-refractory chronic graft versus host disease patients treated with ruxolitinib, ibrutinib, or belumosudil. Bone Marrow Transpl. 2025;60:1410–2.